Atropos Health Secures $33M for AI-Powered Healthcare Platform

Aiming to Bridge the Evidence Gap

Atropos Health, a leader in real-world data platforms, has made significant strides toward its mission of closing the evidence gap in healthcare by securing $33 million in series B funding. This substantial investment is set to accelerate the company’s growth and enhance its AI-driven capabilities.

Founded in 2019 as a spin-out from Stanford University’s “Green Button” technology, Atropos Health developed a consultation service that uses real-world evidence to assist doctors in making informed clinical decisions. The platform answers critical clinical questions, such as identifying the most effective treatments for specific cancer patients.

Innovations in Real-World Data and AI

In a bid to scale its operations, Atropos launched Geneva OS and a chatbot interface called ChatRWD last fall. This technology drastically reduces the time required to generate high-quality, publication-grade evidence from months to mere minutes. According to Atropos, this innovation marks a significant leap in the efficiency of producing real-world evidence, empowering healthcare professionals with the tools to make faster, more informed decisions.

The evidence gap in healthcare treatment guidelines is a well-documented issue. A 2017 BMJ study revealed that only 18% of clinical recommendations by primary care physicians are based on current evidence. This gap is largely due to clinical trials excluding about 70% of the U.S. population. Atropos Health CEO and co-founder Brigham Hyde, Ph.D., highlights the abundance of healthcare data available today, which can be transformed into high-quality evidence at scale using their technology.

Speeding Up Research and Clinical Decision-Making

Traditional observational research on real-world data often takes weeks or months to produce evidence. Atropos Health’s Geneva OS, developed in collaboration with Stanford’s Nigam Shah, Ph.D., and Saurabh Gombar, M.D., Ph.D., leverages vast amounts of de-identified patient data from electronic medical records (EMRs). This system can rapidly generate observational study reports, transforming the speed and transparency of clinical research.

Hyde, in a demonstration of the ChatRWD technology, queried about the effects of an osteoporosis drug among female cancer patients. The AI-powered chatbot swiftly proposed study design enhancements and produced a publication-grade study in under three minutes. This rapid turnaround is poised to revolutionize life sciences, where similar studies traditionally take weeks or months, thereby attracting the interest of healthcare professionals and pharmaceutical companies.

Commitment to Accuracy and Transparency

Atropos Health places a strong emphasis on the importance of accuracy and transparency in AI-generated healthcare results. The ChatRWD framework is built to minimize the risk of ‘hallucinations’ or errors, a critical feature for clinical evidence reliability, providing healthcare professionals and strategic partners with confidence in the technology’s integrity.

The company plans to release a study next month to further demonstrate its approach and accuracy’s benefits in evidence generation. This study is expected to solidify Atropos Health’s position as a trusted platform in the healthcare and life sciences sectors.

Strategic Partnerships and Future Plans

The recent funding round was led by Valtruis and supported by existing investors like Breyer Capital, Emerson Collective, and Presidio Ventures. New strategic investors include Cencora Ventures, McKesson Ventures, and Merck GHI Fund. With this investment, Atropos Health has raised a total of $53.8 million to date.

Atropos Health aims to become the largest international federated healthcare data network, with access to over 200 million unique patient records. The startup is also focused on building strategic partnerships with pharmaceutical companies and healthcare organizations. Notably, they have partnered with Janssen Research & Development to accelerate clinical development through real-world data analysis, demonstrating the value and importance of strategic partnerships in their growth strategy.

Furthering its reach, Atropos has joined forces with Cencora to bring its evidence platform to oncology and specialty care. The company also sees potential in supporting value-based care through partnerships like the one with Arcadia, enhancing its data platform with Atropos’ evidence generation capabilities.

Expanding Internationally

Atropos Health is also eyeing global expansion, with plans to accelerate commercial opportunities outside the U.S., focusing initially on Japan and Brazil. Strategic investments from Presidio Ventures, Samsung Next, Gaingels, and Audere Capital support this international growth.

In summary, Atropos Health’s innovative AI-driven platform is set to revolutionize real-world evidence generation, significantly impacting clinical research and decision-making. With substantial new funding and strategic partnerships, the company is well-positioned to lead the charge in transforming healthcare data into actionable, high-quality evidence.

---

Like this article?  Keep up to date with AI news, apps, tools and get tips and tricks on how to improve with AI.  Sign up to our Free AI Newsletter

Also, come check out our free AI training portal and community of business owners, entrepreneurs, executives and creators. Level up your business with AI ! New courses added weekly. 

You can also follow us on X